Evidence map›Paper›PMID 39787607›Full record

ArticleBlood advances2025

Treatment holidays in patients with Erdheim-Chester disease receiving vemurafenib: a prospective pilot study.

Francesco Pegoraro, Francesco Catamerò, Federica Allegretta, Giulia Palazzini, Francesco Peyronel, Eli L Diamond, Augusto Vaglio

Abstract read
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Kidney Involvement in Erdheim-Chester Disease.Kidney international reports · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francesco PegoraroDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0000-0002-4954-5744
Francesco CatameròDepartment of Health Sciences, University of Florence, Florence, Italy.ORCID 0009-0001-5633-9025
Federica AllegrettaDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Giulia PalazziniDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Francesco PeyronelDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0000-0001-8470-1952
Eli L DiamondDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5456-5961
Augusto VaglioDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.ORCID 0000-0002-3814-9172

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39787607
PMCPMC12051115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.